Skip to main content
. Author manuscript; available in PMC: 2022 Sep 22.
Published in final edited form as: J Vis Exp. 2021 Sep 22;(175):10.3791/62617. doi: 10.3791/62617

Figure 3. Treatment of BCBM organotypic brain slices with paclitaxel.

Figure 3.

(A) Brain slices derived from mice intracranially injected with MDA-MB-231BR-GFP-Luciferase cells treated with DMSO or following treatment of paclitaxel at 40 nM, 80 nM, 160 nM and 320 nM for 10 days, replenishing the medium every 48 h and allowed to grow for the indicated days (image magnification 20x, scale bar: 200 μm). Quantification of tumor growth at indicated day (control n = 6, Paclitaxel n = 3) (bottom). Student’s t-test reported as mean ± SEM. * p < 0.05. (B) Ex vivo brain slice as treated in (A) with either DMSO or 320 nM paclitaxel were collected, fixed, and assayed for GFP, CC3, and DAPI (image magnification 20x, scale bar: 200 μm). (C) Ex vivo brain slice as treated in (A) (without tumor) with either DMSO or 320 nM paclitaxel were collected at day 10 and analyzed for cell viability (MTS assay). As a positive control, slices were treated with paraformaldehyde (PFA) that renders the brain slices inviable (n = 3) Student’s t-test reported as mean ± SEM. * p < 0.05. (D) Ex vivo brain slice as treated in (A) (without tumor) with either DMSO or 320 nM paclitaxel were collected, fixed, and assayed for CC3 and DAPI (image magnification 20x, scale bar: 200 μm). Please click here to view a larger version of this figure.